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Superior localisation and imaging of radiolabelled monoclonal antibody
E48 F(ab'), fragment in xenografts of human squamous cell carcinoma
of the head and neck and of the vulva as compared to monoclonal
antibody E48 IgG
M. Gerretsen', J.J. Quakl, J.S. Suhl, M. van Walsuml, C.J.L.M. Meijer2, G.B. Snow' &
G.A.M.S. van Dongen'
Departments of'Otolaryngology/Head and Neck Surgery and2Pathology, Free University Hospital Amsterdam, The Netherlands.
Summary Monoclonal antibody (MAb) E48 and its F(ab')2 fragment, radiolabelled with "'I, were tested for
tumour localisation and imaging in nude mice bearing a squamous cell carcinoma xenograft line derived from
a head and neck carcinoma (HNX-HN) or from a vulva carcinoma (VX-A431). MAb IgG or F(ab')2
fragments were injected in parallel and at day 1, 2, 3 and 6 or 7, mice were either scanned with a gamma
camera or dissected for determination of isotope biodistribution. In HNX-HN bearing mice, E48 IgG as well
as F(ab')2 showed highly specific localisation in tumour tissue. The mean tumour uptake (n = 4) expressed as
the percentage of the injected dose per gram of tumour tissue (percentage ID/g) of IgG was 11.9% at day 1
and increased to 14.6% at day 6 whereas percentage ID/g of F(ab')2 was 7.2% at day 1 and decreased during
subsequent days. Tumour to blood ratios (T/B) at day I were 1.2 for IgG and 13.6 for F(ab')2 and reached a
maximum at day 6 with values of 6.4 and 54.2 respectively. In VX-A431 bearing mice, only E48 F(ab')2
showed preferential localisation in tumour tissue. At day 1, Percentage ID/g of IgG was 3.7 and T/B was 0.3,
while percentage ID/g of F(ab')2 was 2.4 and T/B was 3.2. Percentage ID/g decreased after day I while T/B
increased. In these experiments no preferential localisation of either isotype matched '251I-labelled control IgG
or F(ab')2 was observed. In F(ab')2 injected HNX-HN bearing mice as well as VX-A431 bearing mice, tumours
could be visualised at day 1 and 2 without any appreciable background activity. With MAb IgG this was also
possible in HNX-HN bearing mice (but not in VX-A431 bearing mice) but only at day 3 and 6. These findings
suggest that the superior tumour to non-tumour ratios render the E48 F(ab')2 fragment more qualified for
specific targeting of radioisotopes to tumour xenografts in this experimental setting.
Of all human neoplasms, squamous cell carcinoma (SCC) is
one of the most common tumour types and represents the
major histological type of neoplasm arising from head and
neck, cervix, skin, and lung. The relative sensitivity of head
and neck SCC for radiation therapy has led us to investigate
the possibility of using monoclonal antibodies (MAb's)
directed against tumour associated antigens (TAA's) to speci-
fically target radioisotopes to SCC tumours.
So far, only a limited number of MAb's to SCC have been
described (Carey et al., 1983; Zenner & Herman, 1981;
Boeheim et al., 1985; Kimmel & Carey, 1986; Fernsten et al.,
1986; Koprowska et al., 1986; Brenner et al., 1982; Kyoizumi
et al., 1985; Myoken et al., 1987; Ranken et al., 1987; Samuel
et al., 1989; Tatake et al., 1989). Most of these antibodies
show considerable cross reactivity with normal tissues or
only show reactivity with SCC of distinct sites of origin.
Among the few MAb's reacting with SCC originating from
various organs are MAB 17.13 (Ranken et al., 1987), an IgM
isotype antibody and thus less suited for in vivo immuno-
localisation studies; MAb 174H.64 (Samuel et al., 1989),
reacting with a cytoskeletal protein, which possibly contains
extracellular domains, and MAb 3F8E3 (Tatake et al., 1989)
which is a low affinity antibody.
We have developed a MAb designated E48, raised against
a SCC of the larynx, which shows strong and selective reac-
tivity to squamous epithelia and their neoplastic derivatives
of various tissue sites (Quak et al., 1990a). Recently, we
described the capacity of MAb E48 IgG for highly specific
delivery of radioisotopes in nude mice carrying human head
and neck SCC xenografts (Quak et al., 1989). However,
F(ab')2 fragments have been demonstrated to have better
tumour to non-tumour ratios in nude mice bearing xeno-
grafts due to a more rapid clearance from the blood (Pervez
et al., 1988; Colapinto et al., 1988; Buchegger et al., 1986;
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Endo et al., 1988). These superior tumour to non-tumour
ratios resulted in much lower background levels and im-
proved tumour images.
In this investigation, we have compared the characteristics
of E48 IgG and E48 F(ab')2 fragment with regard to biodis-
tribution and imaging in nude mice bearing SCC xenografts.
Two xenograft lines, the head and neck SCC xenograft line
HNX-HN and the vulva SCC xenograft line VX-A431, were
selected from a panel of xenograft lines based on the E48
antigen expression. These tumours represent the hetero-
geneity of the E48 immunohistochemical reaction pattern as
observed in 92 human tumours and eight SCC xenograft
lines available at our laboratory. Immunohistochemical
examination of E48 expression in the HNX-HN line revealed
strong homogenous membrane bound expression and to a
lesser extent cytoplasmatic expression while the E48 expres-
sion pattern in the VX-A431 line was shown to be moderate
and diffuse.
Materials and methods
MAb IgG andF(ab')2fragments
MAb E48 (IgGI) detects a 22 kDa surface antigen which, in
normal tissues, is exclusively expressed in stratified squamous
epithelia and transitional epithelia (Quak, 1990a). So far
tested, MAb E48 reacted with 91 out of 93 SCC of head and
neck, lung, cervix and skin, while out of 42 non-SCC
tumours, 40 showed no binding. The isotype-matched control
antibody JSB-1, directed against the P-glycoprotein related to
multidrug resistance and not reactive with the xenograft in
our study, has been described in detail elsewhere (Scheper et
al., 1988). Hybridomas were grown either in tissue culture or
as ascites in Balb/c mice. To purifiy the antibodies, the
ascites was filtered through a 0.22gLm filter and loaded on a
protein A column (Pharmacia, Uppsala Sweden). Eluted frac-
tions were tested for immunoreactivity and dialysed against
0.9% sodium chloride. Protein concentration was determined
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in the BioRad (Richmond, CA) micro assay procedure.
Purified MAb E48 and JSB-1 were digested with 4% (w/w)
pepsin (Pierce) for 18 h at 37°C in 25 mM sodium acetate
buffer (pH 4.0). The reaction was terminated by addition of
2M Tris to bring the pH at 8.0. After extensive dialysis
versus 0.9% sodium chloride, the F(ab')2 fragments were
further purified by Protein A Sepharose column chromato-
graphy followed by elution with 300 mM sodium chloride in
20 mm phosphate buffer (pH 7.4), over a Sephacryl S-200
column (Pharmacia). After dialysis versus 0.9% sodium
chloride and concentrating of the protein preparation, the
protein concentration was determined. Purity of MAb and
F(ab')2 preparations was evaluated by SDS polyacrylamide
gel electrophoresis under non-reducing conditions and
appeared to be more than 95%.
Nude mice xenografts
Female nude mice (NMRI, 25-32 g Harlan Olac, Zeist, The
Netherlands) were 8-10 weeks old at the time of the experi-
ments. The head and neck SCC xenograft line HNX-HN was
established by subcutaneous implantation of tumour frag-
ments measuring 3 x 3 x 1 mm, in the lateral thoracic region
on both sides of nude mice. The head and neck xenograft
line had been established from a T4N2 squamous cell car-
cinoma of the base of the tongue from a 54-year-old female
patient. The vulva xenograft line VX-A431 was established
by injecting in vitro cultured A431 cells subcutaneously. The
A431 cell line was kindly provided by Dr B. Defize,
Hubrecht Laboratorium Utrecht, The Netherlands. Both
xenograft lines were maintained by serial s.c. transplantation.
Radioiodination
lodination of IgG and F(ab')2 fragments was performed
essentially as described by Haisma et al. (1986). 500g of IgG
or F(ab')2 fragment was mixed with 1 mCi 1251 or 1311 and
specific activity of the conjugate was determined. After
removing excess unbound iodine, percentage of incorporated
radioactivity was determined.
MAb IgG and F(ab')2 in vitro binding assays
The binding characteristics of radiolabelled MAb E48 and
E48 F(ab')2 were analysed by immunoreactivity and affinity
assays. The immunoreactivity assay was performed essen-
tially as described by Lindmo et al. (1984). In short, A431
cells were fixed in 0.1% glutaraldehyde and six serial dilu-
tions, ranging from 5 x 106 cells per tube to 3.1 x 105 cells
per tube, were made with 1% bovine serum albumin (BSA)
in PBS. 10,000cpm of the labelled MAb or F(ab')2 fragment
were added to the tubes and incubated overnight at room
temperature. Excess unlabelled MAb or F(ab')2 fragment was
added to the last sample to determine non-specific binding.
Cells were spun down and radioactivity in the pellet and
supernatant was determined in a gamma counter and the
percentage bound and free radiolabelled MAb was calculated
(LKB-Wallac 1218 CompuGamma). Data were graphically
analysed in a modified Lineweaver Burk plot and the
immunoreactive fraction was determined by linear extrapola-
tion to conditions representing infinite antigen excess.
The affinity assay was performed essentially as described
by Badger et al. (1987). In short, 5 x 106 fixed A431 cells in
PBS containing 1% BSA were incubated overnight at room
temperature with 5,000 cpm of the labelled MAb or F(ab')2
fragment and a serial dilution of unlabelled MAb or F(ab')2
fragment. The concentration of the unlabelled MAb or
F(ab')2 fragment was chosen several times higher and several
times lower than the concentration of labelled MAb or
F(ab')2 as calculated from the specific activity. Cells were
spun down and radioactivity in the pellet and supernatant
was determined in a gamma counter. Data were graphically
analysed by Scatchard analysis and affinity constant and
number of antigenic sites per cell was determined. Both the
immunoreactivity assay and the affinity assay were performed
in triplo.
Biodistribution
In vivo tissue distribution was studied in nude mice bearing human squamous cell carcinoma xenografts of the head and
neck (HNX-HN) or of the vulva (VX-A431), following i.v.
administration of 10sCi '"1I E48 IgG and 10 Ci 125I JSB-1
IgG or 10ltCi E48 F(ab')2 fragment and 10;LCi 1251I JSB-1
F(ab')2 fragment. Mice were bled, killed and dissected 1, 2, 3
and 6 days after i.v. injection (HNX-HN mice) or 1, 2, 3 and
7 days after i.v. injection (VX-A431 mice). For each day, 3 or
4 mice were used. Organs were immediately removed, placed in 5 ml plastic tubes and weighed. Samples were taken from
blood, urine, tumour, liver, spleen, kidney, heart, stomach, jejenum, colon, bladder, sternum, muscle, lung, skin and
tongue. After weighing, all organs and tumours were counted
in a dual isotope gamma counter. The antibody uptake in the
tumour and other tissues was calculated as the percentage of
the injected dose per gram of tissue (percentage ID/g). The
specific localisation index (SLI) was calculated by dividing the uptake of the specific MAb or F(ab')2 fragment (E48) by the uptake of the non-specific MAb or F(ab')2 fragment (JSB-1) into the tumour.
Radioimmunoscintigraphy
Mice were killed by cervical dislocation and placed under the
camera. Two mice were scanned simultaneously with an Ohio
gamma camera (Sigma 410 S); 100,000 cpm were obtained
and data were stored in a computer (PDP 1134 computer system) for further analysis and production ofcolour images.
Immunohistochemistry
Expression of the E48 antigen in the xenografts was assessed
on frozen tissue sections by the biotin-avidin peroxidase tech-
nique. Therefore, the E48 MAb was labelled with biotin.
Biotin-N-hydroxysuccimide in DMF was added to a solution
of protein-A purified antibody in 0.1 M bicarbonate buffer
(pH 8.5) in a ratio of 1: 10 (w/w). After mixing, the solution
was gently stirred at room temperature for 1 h and finally dialysed against several changes of PBS. After incubating frozen sections with biotinylated MAb, the sections were
washed three times with PBS and incubated with a pre- formed avidin-biotin peroxidase complex (Vectastain ABC
kit, Vector, Burkingame, CA). The peroxidase label was
developed with diaminobenzidinetetrahydrochloride (DAB, Sigma) plus H202.
Results
Immunohistochemistry
The expression of the E48 antigen in the xenograft lines HNX-HN and VX-A431 was assessed by the biotin-avidin
peroxidase technique. Frozen xenograft sections were incu- bated with protein-A purified biotinylated E48 and JSB-1. E48 showed strong membrane and to a lesser extent cytoplas- matic staining on frozen sections of the HNX-HN xenograft (Figure 1). On sections of the VX-A431 xenograft E48 showed a moderate and diffuse binding pattern (Figure 2). No reactivity was observed with JSB-1 with either xenograft.
Radiolabelling ofMAb andF(ab')2fragments
In the experiment with HNX-HN mice as well as VX-A431
mice, labelling of 500pg E48 IgG with 1 mCi "'1I resulted in
a specific activity of 0.821Cipg-'. Labelling of 500fig E48
F(ab')2 fragment with 1 mCi 131I resulted in a specific activity of 0.68ftCijg-' in case of the experiment with HNX-HN, while labelling of290yig E48 F(ab')2 fragment with 1 mCi "'1I
resulted in a specific activity of 1.13fsCif.g' in case of the
experiment with VX-A431. Labelling of 500 fig control MAb
JSB-1 IgG or control JSB-1 F(ab')2 fragment with 1 mCi 1251 resulted in specific activities of 0.81 ltCi ig-' and 0.75jsCiRADIOIMMUNOIMAGING OF SQUAMOUS CELL CARCINOMA XENOGRAFTS IN NUDE MICE 39
Figure 1 Section of xenograft HNX-HN, stained with
biotinylated MAb E48 by indirect immunoperoxidase method.
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Figure 2 Section of xenograft VX-A431, stained with
biotinylated MAb E48 by indirect immunoperoxidase method.
tLg- , respectively. More than 98% of the iodine was bound,
as revealed by TCA precipitation.
In vitro immunoreactivity andaffinity assays
As determined by the modified Lineweaver-Burke plot, the
immunoreactivity fractions of E48 IgG and E48 F(ab')2 frag-
ments at infinite antigen excess were > 0.95 in all experi-
ments. The affinity constants were 1.5 x 1010 M- for E48
IgG and 1.2 x 1010 M-l for E48 F(ab')2 fragment as deter-
mined by the Scatchard plot. A431 cells expressed 3.3 x 104
binding sites/cell. Binding of control IgG and F(ab')2 frag-
ment to A431 cells was <2% of the input doses.
Pharmacokinetics ofMAb and F(ab')2fragments
At day 1, 2, 3 and 6 (HNX-HN) or 1, 2, 3 and 7 (VX-A431),
serum samples were collected to determine free iodine. Less
than 5% free iodine was present as revealed by TCA precip-
itation. At day 1 after injecting the labelled MAb IgG and
F(ab')2 9.32 to 11.66% ID/g E48 IgG and 12.11 to 12.21%
ID/g JSB-1 IgG was present in the blood, whereas 0.53 to
0.74% ID/g E48 F(ab')2 fragment and 0.83 to 1.30% ID/g
JSB-l F(ab')2 was present in the blood, indicating a much
faster clearance of F(ab')2 fragments from the blood as com-
pared to whole IgG.
Biodistribution
Tumour uptake ofE48 IgG and F(ab')2fragment in HNX-HN
bearing mice The amount of 1311 E48 IgG and 13'I E48
F(ab')2 fragment in the xenografts and various organs, ex-
pressed as the average percentage of radioactivity of the
injected dose per gram of tissue (percentage ID/g), is shown
in Figures 3a and 4a. Table Ia and lb show the tumour to
Figure 3 Biodistribution data for a 10IACi "3'-labelled E48 IgG
and b 10ICi 2'I-labelled JSB-1 IgG in athymic mice bearing
HNX-HN xenografts. At 1 (black), 2 (hatched), 3 (dotted) and 6
(open) days following i.v. injection tissues were dissected and
counted and the percentage injected dose per gram (percentage
ID/g) was calculated. Each day 3-4 mice were dissected.
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Figure 4 Biodistribution data for a 10 yCi '3'I-labelled E48
F(ab')2 and b 10ltCi '25I-labelled JSB-1 F(ab')2 in athymic mice
bearing HNX-HN xenografts. At 1 (black), 2 (hatched), 3 (dot-
ted) and 6 (open) days following i.v. injection tissues were
dissected and counted and the percentage injected dose per gram
(percentage ID/g) was calculated. Each day 3-4 mice were
dissected.
tissue ratios of E48 IgG and E48 F(ab')2 fragment as well as
ofcontrol IgG and control F(ab')2, calculated by dividing the
percentage ID/g of tumour tissue by the percentage ID/g of
various non-tumour tissues. At day 1, 2, 3 and 6, the percen-
tage ID/g in tumours of 131I E48 IgG injected mice was 11.9
(mean tumour weight ± standard error of the mean
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Table Ia Tumour to tissue ratio of E48 and JSB-1 IgG in HNX-HN
bearing mice
Tumour to tissue ratio ofE48 IgG
Day ) Day 2 Day 3 Day 4
Blood 1.2±0.4 2.1±0.3 3.3±1.0 6.4±2.4
Sternum 11.7±4.1 17.2±6.2 28.5±9.9 68.3± 38.8
Liver 5.7± 3.3 7.8±2.4 16.0±6.6 26.0±9.2
Spleen 7.9±4.1 10.0±2.2 20.5± 10.1 40.7±22.0
Kidney 4.9±1.8 7.2±2.1 13.0±5.2 25.8 10.0
Colon 15.9±5.4 15.2±6.0 36.5± 15.2 72.3 39.7
Tumour to tissue ratio ofJSB-I IgG
Day I Day 2 Day 3 Day 4
Blood 0.3±0.1 0.4±0.1 0.9±0.5 0.3±0.1
Sternum 2.8±0.3 3.0±0.3 7.5±7.1 3.4±0.6
Liver 1.3±0.5 1.4±0.4 4.1±4.0 1.5±0.4
Spleen 1.7±0.5 1.8±0.1 4.7±3.7 2.3±0.4
Kidney 1.1±0.1 1.3±0.2 3.3±3.0 1.4±0.3
Colon 3.8±0.2 3.2± 1.1 9.9±9.2 4.6± 1.0
Tablelb Tumour to tissueratio ofE48 andJSB-1 F(ab')2inHNX-HN
bearing mice
Tumour to tissue ratio ofE48 F(ab')2
Day ) Day 2 Day 3 Day 4
Blood 13.6±5.0 29.4±6.8 49.4±22.2 54.2±8.9
Sternum 71.4±36.8 231.1 ±68.8 329.4± 115.1 172.5±46.2
Liver 32.5± 16.0 93.8± 13.9 134.8± 51.2 141.2±16.5
Spleen 33.8± 16.6 105.6±20.6 143.2± 59.1 176.2± 34.2
Kidney 15.3±7.7 60.4±8.1 76.9±25.9 93.8±4.9
Colon 82.9±40.0 220.6±62.7 297.0± 104.3 225.1 ± 50.3
Tumour to tissue ratio ofJSB-1 F(ab')2
Day I Day 2 Day 3 Day 4
Blood 0.5±0.1 0.6±0.1 1.1±0.4 0.5±0.1
Sternum 4.2±0.8 5.7±0.4 7.9±2.8 4.3±0.8
Liver 1.9±0.6 2.8±0.8 3.3± 1.4 1.4±0.8
Spleen 1.9±0.4 3.1 ±0.4 3.9± 1.6 2.9±0.4
Kidney 0.7±0.3 2.0±0.6 2.6± 1.4 1.8±0.2
Colon 5.3± 1.3 6.8± 1.5 9.5±3.4 6.9±0.4
Table Ila Specific localisation index ofE48 IgG in HNX-HN bearing
mice
Day I Day 2 Day 3 Day 6
3.65 4.52 4.35 5.79
Table Ilb Specific localisation index of E48 F(ab')2 in HNX-HN
bearing mice
Day I Day 2 Day 3 Day 6
9.03 6.66 18.45 28.4
Table Illa Tumour to tissue ratio ofE48 and JSB-1 IgG in VX-A431
bearing mice
Tumour to tissue ratio ofE48 IgG
Day I Day 2 Day 3 Day 4
Blood 0.3±0.1 0.3±0.1 0.6±0.1 1.5±0.6
Sternum 3.3±0.9 3.6±0.8 5.9±0.8 12.2±4.0
Liver 1.3±0.3 1.5±0.5 2.2±0.4 6.6±2.5
Spleen 1.8±0.4 1.9±0.3 3.0±0.3 10.0±4.6
Kidney 1.3±0.1 1.4±0.3 2.1±0.5 6.5±4.1
Colon 4.0±0.4 4.2±1.3 6.3±1.1 15.6±7.0
Tumour to tissue ratio ofJSB-1 IgG
Day ) Day 2 Day 3 Day 4
Blood 0.4±0.3 0.3±0.1 0.4±0.1 0.7±0.2
Sternum 4.6±3.9 3.7±0.7 4.9± 1.0 6.5± 1.1
Liver 1.7± 1.1 1.5±0.2 1.8±0.5 3.7±0.9
Spleen 2.5±2.2 1.9±0.3 2.3±0.3 5.5± 1.9
Kidney 1.9±1.5 1.3±0.1 1.7±0.5 3.5±1.2
Colon 5.2±3.8 4.9± 1.1 5.3± 1.2 9.0±2.8
Table IlIb Tumour to tissue ratio of E48 and JSB-1 F(ab')2 in
VX-A431 bearing mice
Tumour to tissue ratio ofE48 F(ab')2
Day I Day 2 Day 3 Day 4
Blood 3.2±0.4 5.7±2.0 7.3±0.6 3.5± 3.0
Sternum 28.9±3.7 51.1±16.5 72.7± 15.2 39.1±23.8
Liver 8.8± 1.7 16.8±6.1 24.7±2.2 12.9±9.9
Spleen 12.7± 1.6 23.5±5.2 38.9±5.8 17.2±8.7
Kidney 6.4±1.6 13.5±5.0 20.4±2.4 11.6±6.9
Colon 25.7±4.9 43.4±24.2 75.2± 11.6 42.6±20.3
Tumour to tissue ratio ofJSB-1 F(ab')2
Day I Day 2 Day 3 Day 4
Blood 0.7±0.1 1.1±0.2 1.5±0.4 0.6±0.4
Sternum 8.7±1.6 12.3±2.4 17.1±5.3 6.5±3.6
Liver 2.5±0.2 4.2±0.9 6.2±1.3 2.8±1.8
Spleen 3.4±0.3 5.9±1.2 8.8±2.7 3.5±1.4
Kidney 1.5±0.4 2.6±0.5 4.0±0.9 2.1±0.9
Colon 7.8±2.2 10.8± 5.5 19.7±6.9 6.7± 3.5
Table IVa Specific localisation index ofE48 IgG in VX-A431 bearing
mice
Day ) Day 2 Day 3 Day 6
1.71 1.14 1.20 1.03
Table IVb Specific localisation index of E48 F(ab')2 in VX-A431
bearing mice
Day I Day 2 Day 3 Day 6
4.10 3.48 2.84 2.30
(m.t.w. ± s.e.m.): 352.6 ± 207.5), 11.9 (m.t.w. ± s.e.m.:
487.3 ± 238.0), 10.2 (m.t.w. ± s.e.m.: 398.6 ± 181.8) and 14.6
(m.t.w. ± s.e.m.: 326.8 ± 268.4) respectively (Figure 3a),
whereas percentage ID/g in tumours of 1311 E48 F(ab')2
injected mice decreased after day 1 from 7.2 (m.t.w. ± s.e.m.:
277.4 ± 185.3) to 4.4 (m.t.w. ± s.e.m.: 368.5 ± 256.2) at day
2, 3.7 (m.t.w. ± s.e.m.: 510.8 ± 316.5) at day 3 and 2.0
(m.t.w. ± s.e.m.: 336.7 ± 203.0) at day 6 (Figure 4a). To ex-
clude the possibility that uptake might be due to non-specific
protein trapping, an isoptye matched antibody and its F(ab')2
fragment were included as a control. The control IgG and
control F(ab')2 did not show any specific accumulation, either
in the tumours or in any organ (Figures 3b and 4b).
Table Ila and Ilb show the specific localisation index (SLI)
of E48 IgG and E48 F(ab')2 fragments, calculated by dividing
the percentage ID/g of specific IgG or F(ab')2 fragment (E48)
in the tumour by the percentage ID/g of control IgG or
F(ab')2 fragment (JSB-1). In the course of the experiment,
SLI of E48 IgG did not change significantly (3.7 at day 1 to
5.8 at day 6), whereas SLI of E48 F(ab')2 fragment reached a
maximum of 28.4 at day 6.
Tumour uptake of E48 IgG and E48 F(ab')2 fragment in
VX-A431 bearing mice The percentage ID/g of 13'I E48 IgG
and 13'I E48 F(ab')2 fragment in xenografts and various
organs was determined as above. Tables Illa and ITlb show
the tumour to tissue ratios of E48 IgG and E48 F(ab')2
fragment. At day 1, 2, 3 and 7, the percentage ID/g in
tumours of E48 IgG injected mice was 3.7 (m.t.w. ± s.e.m.:
370.3 ± 247.2), 3.3 (m.t.w. ± s.e.m.: 525.3 ± 237.5), 3.5
(m.t.w. ± s.e.m.: 409.3 ± 142.9) and 3.0 (m.t.w. ± s.e.m.:
356.3 ± 248.1), respectively (data not shown), whereas
percentage ID/g in E48 F(ab')2 injected mice decreased
steadily after day 1, from 2.4 (m.t.w. ± s.e.m.: 640.4 ± 573.6)
to 1.4 (m.t.w. ± s.e.m.: 621.2 ± 605.6), 0.9 (m.t.w. ± s.e.m.:
274.6 ± 145.9) and 0.2 (m.t.w. ± s.e.m.: 290.8 ± 135.0),
respectively (Figure Sa). Table IVa and IVb show the SLI of
E48 IgG and E48 F(ab')2 fragment. E48 IgG did not show a
pronounced specific localisation in the tumour xenografts, as
reflected by the low SLI of E48 IgG (Table IVa). E48 F(ab')2RADIOIMMUNOIMAGING OF SQUAMOUS CELL CARCINOMA XENOGRAFTS IN NUDE MICE 41
4
3
2
Sterum Ittumor Sisum
Figure 5 Biodistribution data for a 10JACi 311-labelled E48
F(ab')2 and b 10 LCi 251I-labelled JSB-1 F(ab')2 in athymic mice
bearing VX-A431 xenografts. At 1 (black), 2 (hatched), 3 (dotted)
and 7 (open) days following i.v. injection tissues were dissected
and counted and the percentage injected dose per gram (percen-
tage ID/g) was calculated. Each day 3-4 mice were dissected.
however did show appreciable specific localisation (Table
IVb), with SLI being 4.1 at its maximum at day 1. The
control IgG (data not shown) and control F(ab')2 (Figure 5b)
did not show any specific accumulation in the tumours nor in
any organ.
Uptake in other organs The percentage of E48 IgG and E48
F(ab')2 fragment in various organs of HNX-HN bearing mice
is presented in Figure 3a and Figure 4a. Only the most
relevant organs are shown, the uptake in heart, stomach,
jejenum, muscle, lung and tongue being comparable to or
lower than uptake in colon. Sternum is shown because of the
presence of haemopoietic tissue. The percentage ID/g of IgG
(data not shown) and E48 F(ab')2 (Figure 5a) in various
organs of VX-A431 bearing mice was essentially the same as
for HNX-HN bearing mice.
Control IgG or control F(ab')2 fragment did not show any
preferential localisation (Tables Ta, Ib, Ila and ITb and
Figures 3b, 4b and 5b).
Radioimmunoscintigraphy
HNX-HN mice E48 IgG and E48 F(ab')2 injected mice were
scanned at several time points following i.v. injection. After
scanning, mice were dissected and biodistribution data were
collected and compared to immunoscintigraphic images.
Each picture in Figures 6a-d, Figures 7a and 7b and Figures
8a and 8b thus represent a different pair of mice being
scanned. Orientation of the left mouse in each picture was
head to tail from top to bottom, orientation of the right
mouse was tail to head from top to bottom. Figure 6a
represents two mice, scanned 1 day after injection of 10 iCi
131T-labelled E48 IgG per mouse. The percentage ID/g of the
xenografts was 10.13, 8.69, 11.87 and 10.49 from left to right
respectively. High blood pool activity, most prominent in the
thoracic cavity, hampered distinction of xenografts on day 1
(Figure 6a) as well as day 2 (Figure 6b). This background
activity only markedly decreased 2 days after injection, after
which timepoint xenografts could be visualised without
appreciable background disturbance (Figure 6c, Figure 6d).
Figure 6 Whole body scintigraphic images of pairs of athymic
mice each bearing one or two subcutaneous HNX-HN xenografts
given an injection of 10liCi "lI E48 IgG. Images were taken at
day I a, day 2 b, day 3 c and day 6 d. Weight ofxenografts in mg
from left to right: a: 577, 575, 463, 464; b: 772, 211, 148, 341; c:
297, 472, 255, 694; d: 252, 379, NX, 766 (NX = no xenograft
present).
Figures 7a and b represent mice being scanned 1 day and 2
days after injection of 10 Ci '3'I-labelled E48 F(ab')2 frag-
ment per mouse. Percentage ID/g at day 1 was of 6.09, 6.12,
8.28 and 9.03 from left to right, respectively (Figure 7a), and
at day 2 percentage ID/g was 4.28, 6.11 and 3.24 and 2.89
from left to right, respectively (Figure 7b). No background
activity could be detected, resulting in images showing only
xenograft localisation of radioisotope.
VX-A431 mice Images of mice injected with 10sCi 31TI-
labelled E48 IgG did not result in identification of xenografts
at any timepoint after injection, due to consistent high blood
pool activity (images not shown). Images of mice injected
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Figure 7 Whole body scintigraphic images of pairs of athymic
mice each bearing one or two subcutaneous HNX-HN xenografts
given an injection of 10 jCi 131l E48 F(ab')2. Images were taken
at day a, day 2 b. Weight of xenografts in mg from left to right:
a: 314, 294, 205, 705; b: 895, 353, 585, 167.
r.O:.
Figure 8 Whole body scintigraphic images of pairs of athymic
mice each bearing one or two subcutaneous VX-A431 xenografts
given an injection of 1OICi 31i1 E48 F(ab')2. Images were taken
at day I a, day 2 b. Weight of xenografts in mg from left to right:
a: 283, 1399, 442, 1810; b: 862, 698, 1677, NX.
with 10 lCi '31I-labelled E48 F(ab')2 however, 1 day (Figure
8a) and 2 days (Figure 8b) after injection, did show xeno-
grafts depicted without significant background disturbance.
Percentage ID/g at day 1 was 2.41, 1.72, 2.16 and 2.08 from
left to right, respectively (Figure 8a) and at day 2 percentage
ID/g was 1.06, 1.11 and 1.03, respectively (Figure 8b).
Discussion
Conjugates of radioisotopes and immunoglobulines or their
fragments are attractive agents for tumour diagnosis and
therapy. However, fragments are cleared more rapidly from
the blood than whole IgG (Pervez et al., 1988; Buchegger et
al., 1986; Endo et al., 1988; Colapinto et al., 1988), resulting
in lower background activity and reducing the radiation dose
to normal tissues. Moreover, fragments lack the Fc region
responsible for nonspecific tissue uptake by Fc receptor bind-
ing and may be less immunogenic in humans (Smith et al.,
1979). Finally, the smaller size of fragments should allow
better tumour penetration than whole IgG. Although these
phenomena hold true for both Fab and F(ab')2, reports
dealing with studies on tumour uptake of whole IgG, F(ab')2
and Fab often show a strong decrease in tumour uptake of
F(ab')2 and Fab when compared to whole IgG and a strong
decrease in tumour to normal tissue ratios of Fab when
compared to F(ab')2, most likely the result of increased
clearance from the blood and a decreased affinity inherent in
the generation of univalent Fab fragments (Buchegger et al.,
1986; Colapinto et al., 1988; Endo et al., 1988; Wahl et al.,
1983).
In this investigation we compared the characteristics of
E48 IgG and E48 F(ab')2 with regard to biodistribution and
imaging parameters in nude mice bearing SCC xenografts. In
a previous study we reported the production of MAb E48
recognising a 22 kDa antigen exclusively expressed in strati-
fied squamous epithelia and transitional epithelium of the
bladder (Quak et al., 1990a,b). In neoplastic tissues, reactivity
with MAb E48 is restricted to squamous cell carcinoma of
head and neck, lung, cervix and skin and to urinary bladder
carcinoma. Reactivity was observed mainly on the membrane
and to a lesser extent within the cytoplasm. Based on
immunohistochemical examination, two xenograft lines were
selected from 8 SCC lines available at our laboratory. The
head and neck xenograft line SCC HNX-HN revealed strong
and homogenous membrane binding of the antibody and
showed a well organised tumour structure with separated
tumour nests in well developed stroma, representing a pat-
tern displayed by the majority of human tumours investi-
gated sofar. The vulva SCC xenograft line VX-A431 revealed
a moderate and diffuse binding pattern of the antibody and
displayed a much less organised tumour tissue structure.
These two tumours represent the extremes of immunohisto-
chemical reaction patterns as observed in 92 human tumours
immunohistochemically stained with MAb E48. In a previous
study, we already demonstrated the capacity of E48 IgG for
specific delivery of radioisotopes to tumours in nude mice
bearing a SCC xenograft line (Quak et al., 1989). In nude
mice bearing the HNX-HN xenograft line, the use of the
F(ab')2 fragment of E48 strongly improved tumour uptake
ratios and localisation specificity when compared directly
with IgG. Although the digestion of IgG for the generation
of F(ab')2 did not significantly alter the affinity of the
radiolabelled conjugate, F(ab')2 did show a decrease in per-
centage ID/g tumour tissue as compared to IgG. Differences
in pharmacokinetics of the conjugates are likely to be the
major factors leading to this decrease. However, the im-
proved tumour uptake ratios and specificity of localisation
resulted in images without background disturbance at day 1
for F(ab')2, whereas IgG did not give comparable images
until day 3. In nude mice bearing the xenograft line VX-
A431, E48 IgG uptake in tumours did not differ from control
IgG, thus failing to reach tumour to non tumour ratios
enabling visualisation of tumour xenografts at any time
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localisation in tumour tissue, and although the percentage
ID/g was almost one third of the percentage ID/g of E48
F(ab')2 in HNX-HN bearing mice and the SLI of F(ab')2 in
VX-A431 bearing mice was less than half the SLI of F(ab')2
in HNX-HN bearing mice, tumours could still well be visual-
ised at day 1. These differences in percentage ID/g and
specificity of localisation between the HNX-HN and VX-
A431 xenograft lines might be due to such variables as
vascularisation, blood vessel morphology and permeability,
tumour microcirculation, necrosis, composition of extracel-
lular matrix and intratumoural hydrostatic pressure, para-
meters likely to be ofconsiderable influence on the efficacy of
non-surgical modalities (Sands et al., 1988; Cobb, 1989; Kal-
linowski et al., 1989; Jain & Wie, 1977; Sweet et al., 1979;
Hori et al., 1986).
Additionally, differences in number and exposition of anti-
genic sites cannot be ruled out as major factors in causing
the differences in localisation of the radiolabelled conjugates
between the two xenograft lines. A lower number of exposed
antigenic sites per cell in the VX-A431 xenograft line as
compared to the HNX-HN xenograft line combined with the
higher penetration capacities of the small E48 F(ab')2 frag-
ment as compared to E48 IgG might very well explain the
inability of E48 IgG to localise specifically in the VX-A431
xenograft line. In this perspective, the differences in localisa-
tion characteristics between the HNX-HN and the VX-A431
xenograft lines might reflect the heterogeneity of expression
and accessibility of antigenic sites in human tumours in the
clinical situation.
In normal tissues, neither E48 IgG nor E48 F(ab')2 showed
any non specfic accumulation in vital organs, including the
radiation sensitive reticuloendothelial system (liver, spleen
and bone marrow). The overall tumour to non-tumour ratios
of F(ab')2 however were several times higher than tumour to
non tumour ratios of IgG. Tumour to non-tumour ratios of
F(ab')2 in VX-A431 bearing mice were still higher than
tumour to non-tumour ratios of IgG in HNX-HN bearing
mice.
So far, only a limited number of MAb's reacting with
human squamous cell carcinoma have been described. Most
of these antibodies show considerable cross reactivity with
other tissues or only show reactivity with SCC of distinct
sites of tissue origin. Additionally, features of these anti-
bodies as isotype, cytoplasmatic localisation of the antigen
and relatively low affinity of the antibody render them less
suited for in vivo localisation studies or application in a
clinical setting.
Within the limitations of our experiments, we have shown
the E48 F(ab')2 fragment to be a promising candidate for
immunodiagnostic application in a clinical setting. Prepara-
tions for a phase I/II clinical study are currently in progress.
The authors wish to thank Dr van Lingen of the Department of
Nuclear Medicine for help with image analysis.
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